Oncology Pharmacy in Your Community - CAPhO
Oncology Pharmacy in Your Community - CAPhO
Oncology Pharmacy in Your Community - CAPhO
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
2007 | NOPS POSTERS<br />
COST-EFFECTIVENESS ANALYSIS OF OXALIPLATIN (ELOXATIN®) IN THE<br />
ADJUVANT TREATMENT OF STAGE III COLON CANCER<br />
Attard C 1 , Maroun J 2 , Alloul K 3 , Grima D 1 , Bernard L 1<br />
1 Cornerstone Research Group Inc, Burl<strong>in</strong>gton, Canada, 2 Ottawa Regional Cancer Centre, Ottawa, Canada,<br />
3 Sanofi -aventis Canada Inc., Laval, Canada<br />
Objective: To determ<strong>in</strong>e the <strong>in</strong>cremental cost per Quality-Adjusted Life-Years (QALY) of FOLFOX - oxaliplat<strong>in</strong> plus 5-fl uorouracil/Leucovor<strong>in</strong><br />
(5FU/LV) compared with 5-FU/LV alone for the adjuvant treatment of stage III colon cancer from the perspective of<br />
Ontario’s M<strong>in</strong>istry of Health.<br />
Design: Patients’ outcomes were modeled from treatment until death us<strong>in</strong>g patient level data from the MOSAIC trial. The data from this<br />
trial was extrapolated based on the relationship between the overall survival (OS) and disease-free survival (DFS), and Canadian life tables.<br />
Utilities were obta<strong>in</strong>ed from the literature. Resource utilization data were derived from the MOSAIC trial and supplemented with data<br />
from the literature. Unit costs were obta<strong>in</strong>ed from the Ontario M<strong>in</strong>istry of Health and Long-Term Care documents, a data abstraction at<br />
London Health Sciences, and the literature. Results were discounted at 5% annually.<br />
Results: Incremental cost-effectiveness ratios of FOLFOX compared to 5FU/LV from the lifetime analysis were Can$14,266 per disease-free<br />
year; Can$23,598 per life year saved and Can$24,104 per QALY. The results were stable for a wide range of <strong>in</strong>puts, but were<br />
most sensitive to assumptions regard<strong>in</strong>g the utility values associated with relapse.<br />
Conclusion: Oxaliplat<strong>in</strong>/5-FU/LV is a cost-effective treatment for stage III colon cancer, with a cost-effectiveness ratio of Can$24,104<br />
per QALY.<br />
Contact Information:<br />
cattard@cornerstone-research.com<br />
Sponsor Information:<br />
sanofi -aventis Canada Inc.<br />
E-mail: el-hadi.wissam@sanofi -aventis.com<br />
Fax : (514) 956-4199<br />
Category of abstract: <strong>Pharmacy</strong> practice and adm<strong>in</strong>istration<br />
NOPS — <strong>Oncology</strong> <strong>Pharmacy</strong> <strong>in</strong> <strong>Your</strong> <strong>Community</strong>, October 26-28, 2007<br />
Page 143
Change language